Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)
China
· Delayed Price · Currency is CNY 31.54
-0.16 (-0.50%)
Apr 3, 2025, 2:45 PM CST
SHA:688180 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,948 | 1,474 | 1,229 | 3,768 | 1,507 | Upgrade
|
| Other Revenue | - | 28.4 | 224.26 | 257.09 | 87.52 | Upgrade
|
| Revenue | 1,948 | 1,503 | 1,453 | 4,025 | 1,595 | Upgrade
|
| Revenue Growth (YoY) | 29.67% | 3.38% | -63.89% | 152.36% | 105.77% | Upgrade
|
| Cost of Revenue | 498.86 | 634.39 | 526.28 | 1,258 | 376.76 | Upgrade
|
| Gross Profit | 1,449 | 868.16 | 927.21 | 2,767 | 1,218 | Upgrade
|
| Selling, General & Admin | 1,532 | 1,381 | 1,285 | 1,377 | 1,128 | Upgrade
|
| Research & Development | 1,275 | 1,937 | 2,384 | 2,069 | 1,778 | Upgrade
|
| Other Operating Expenses | 19.7 | 7.54 | 6.03 | 7.07 | 7.72 | Upgrade
|
| Operating Expenses | 2,808 | 3,344 | 3,675 | 3,453 | 2,913 | Upgrade
|
| Operating Income | -1,358 | -2,476 | -2,748 | -686.06 | -1,695 | Upgrade
|
| Interest Expense | -51.35 | -29.01 | -29.37 | -21.83 | -29.39 | Upgrade
|
| Interest & Investment Income | 43.63 | 173.42 | 61.02 | 30.98 | 20.28 | Upgrade
|
| Earnings From Equity Investments | -35.03 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 8.27 | -2.66 | 50.05 | -39.94 | -11.67 | Upgrade
|
| Other Non Operating Income (Expenses) | 56.29 | -38.71 | -0.8 | 0.13 | -0.99 | Upgrade
|
| EBT Excluding Unusual Items | -1,336 | -2,373 | -2,667 | -716.72 | -1,717 | Upgrade
|
| Gain (Loss) on Sale of Investments | -21.91 | -149.18 | -51.21 | 65.75 | 40.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.81 | 28.89 | 22.37 | 0.78 | 1.12 | Upgrade
|
| Other Unusual Items | -0.06 | 1.55 | 18.73 | 55.2 | 2.84 | Upgrade
|
| Pretax Income | -1,359 | -2,492 | -2,677 | -595 | -1,672 | Upgrade
|
| Income Tax Expense | 22.55 | 43.99 | -93.11 | 135.53 | -3.82 | Upgrade
|
| Earnings From Continuing Operations | -1,382 | -2,536 | -2,584 | -730.53 | -1,669 | Upgrade
|
| Net Income to Company | -1,382 | -2,536 | -2,584 | -730.53 | -1,669 | Upgrade
|
| Minority Interest in Earnings | 99.18 | 252.26 | 196.03 | 9.62 | 0 | Upgrade
|
| Net Income | -1,282 | -2,283 | -2,388 | -720.91 | -1,669 | Upgrade
|
| Net Income to Common | -1,282 | -2,283 | -2,388 | -720.91 | -1,669 | Upgrade
|
| Shares Outstanding (Basic) | 985 | 984 | 918 | 890 | 822 | Upgrade
|
| Shares Outstanding (Diluted) | 985 | 984 | 918 | 890 | 822 | Upgrade
|
| Shares Change (YoY) | 0.07% | 7.16% | 3.20% | 8.28% | 5.58% | Upgrade
|
| EPS (Basic) | -1.30 | -2.32 | -2.60 | -0.81 | -2.03 | Upgrade
|
| EPS (Diluted) | -1.30 | -2.32 | -2.60 | -0.81 | -2.03 | Upgrade
|
| Free Cash Flow | - | -2,838 | -2,170 | -1,507 | -2,037 | Upgrade
|
| Free Cash Flow Per Share | - | -2.88 | -2.36 | -1.69 | -2.48 | Upgrade
|
| Gross Margin | 74.39% | 57.78% | 63.79% | 68.74% | 76.38% | Upgrade
|
| Operating Margin | -69.70% | -164.79% | -189.06% | -17.05% | -106.28% | Upgrade
|
| Profit Margin | -65.82% | -151.97% | -164.30% | -17.91% | -104.62% | Upgrade
|
| Free Cash Flow Margin | - | -188.85% | -149.31% | -37.44% | -127.71% | Upgrade
|
| EBITDA | -1,097 | -2,215 | -2,513 | -476.32 | -1,576 | Upgrade
|
| EBITDA Margin | -56.32% | -147.43% | -172.86% | -11.83% | -98.80% | Upgrade
|
| D&A For EBITDA | 260.78 | 260.78 | 235.47 | 209.74 | 119.31 | Upgrade
|
| EBIT | -1,358 | -2,476 | -2,748 | -686.06 | -1,695 | Upgrade
|
| EBIT Margin | -69.70% | -164.79% | -189.06% | -17.04% | -106.28% | Upgrade
|
| Revenue as Reported | - | 1,503 | 1,453 | 4,025 | 1,595 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.